Title

Tumour extracellular vesicle‐derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement‐dependent cytotoxicity of tumour cells.

Authors

Mao, Xiaowen; Zhou, Longyin; Tey, Sze Keong; Ma, Angel Po Yee; Yeung, Cherlie Lot Sum; Ng, Tung Him; Wong, Samuel Wan Ki; Liu, Bonnie Hei Man; Fung, Yi Man Eva; Patz, Edward F.; Cao, Peihua; Gao, Yi; Yam, Judy Wai Ping

Abstract

The complement system is involved in the immunosurveillance of pathogens and tumour cells. Proteomic profiling revealed that extracellular vesicles (EVs) released by metastatic hepatocellular carcinoma (HCC) cells contained a significant number of complement proteins. Complement Factor H (CFH), an abundant soluble serum protein that inhibits the alternative complement pathway, was found to be highly expressed in EVs of metastatic HCC cell lines. Here, we investigated the functional role of EV‐CFH and explored the therapeutic efficacy of targeting EV‐CFH with an anti‐CFH antibody in HCC. The results showed that EVs that are enriched in CFH promoted HCC cell growth, migration, invasiveness and enhanced liver tumour formation in mice. EV‐CFH also promoted metastasis, which was significantly abrogated when treated with an anti‐CFH antibody. These findings demonstrate an unexplored function of EV‐CFH in protecting HCC cells by evading complement attack, thereby facilitating tumorigenesis and metastasis. Lastly, we demonstrated the therapeutic efficacy of an anti‐CFH antibody in suppressing tumour formation in a syngeneic mouse model. This study suggests a new therapeutic strategy for HCC, by inhibiting EV‐CFH with a tumour specific anti‐CFH antibody.

Subjects

COMPLEMENT factor H; BLOOD proteins; EXTRACELLULAR vesicles; COMPLEMENT receptors; METASTASIS; NEOPLASTIC cell transformation

Publication

Journal of Extracellular Vesicles, 2020, Vol 10, p1

ISSN

2001-3078

Publication type

Academic Journal

DOI

10.1002/jev2.12031